Skip to content
Search

Latest Stories

More than 60% of UK adult supports idea of 'GPs referral to pharmacists', survey reveals

More than half of people (52%) do not feel confident in treating backache and less than half (44%) uses community pharmacists’ advice as their first step on self-treatable conditions, a self-care attitudes 2022 survey has revealed.

PAGB, the consumer healthcare association, surveyed over 2,000 adults across the UK about their attitudes towards self-care and access to health services.


According to the survey, the public is in favour of self-care but many people lack the confidence and knowledge to care for the most common self-treatable conditions including backaches, headaches, diarrhoea and constipation.

Four in five respondents (79%) said that people should take more responsibility for their own health and three-quarters (73%) believe that the NHS should make self-treatment easier.

Behaviours around the current use of pharmacy varied – with less than half (44%) using community pharmacists as their first step in in getting advice on self-treatable conditions – but longer term attitudes were encouraging, with 69% supporting the idea of GPs being able to make referrals to pharmacists. Respondents also supported expanding the role of pharmacists so that their skills can be better utilised.

The Self-Care Attitudes 2022 survey report, released to coincide with the start of Self Care Week (14-20th November), concludes that “Government must act now to harness the positive move towards self-care and lock in the changes of this time-limited opportunity”.

Commenting on the survey results, Janet Morrison, PSNC Chief Executive, said: “The COVID-19 pandemic saw a significant shift towards self-care and growing public reliance on community pharmacies and from the reports we are getting from pharmacies the demand for advice and support is showing no signs of slowing down. The PAGB Survey results once again highlight just how many people would like their community pharmacies to be able to do even more to help them.

If the Government and NHS really want to make a dent in the COVID backlog and build a sustainable healthcare system for the future, they must continue to develop self-care confidence amongst the public, and community pharmacy can help with that. PSNC has long called for pharmacy to be used as the first port of call for people seeking advice and support in managing minor illness, however, we cannot ignore the growing pressures community pharmacy teams are facing. These cost and capacity pressures must be urgently addressed by Government and the NHS before the public loses these community assets. A fully funded ‘Pharmacy First’ service would help to address some of these issues.”

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less